FDA Advisory Committee Will Review ESAs In The Renal Setting Oct. 18
This article was originally published in The Pink Sheet Daily
Executive Summary
Meeting also could be next step in the process of determining whether safety issues are enough to drive changes to erythropoiesis-stimulating agent reimbursement at CMS.
You may also be interested in...
Can Amgen Stop The Bleeding As FDA Presses For A Low-Dose Aranesp Trial?
CardioRenal Advisory Committee will discuss whether there should be a trial testing lower dosing limits in CKD patients. With sales declines a forgone conclusion regardless, Amgen hopes to avoid the expense of a complex study.
Can Amgen Stop The Bleeding As FDA Presses For A Low-Dose Aranesp Trial?
CardioRenal Advisory Committee will discuss whether there should be a trial testing lower dosing limits in CKD patients. With sales declines a forgone conclusion regardless, Amgen hopes to avoid the expense of a complex study.
San Francisco-based FibroGen Gets SFDA Nod Through Green Channel Procedure
HONG KONG - San Francisco-based FibroGen announced that Chinese regulators approved the start of clinical trials of novel therapy FG-4592 for anemia associated with chronic kidney disease. The approval was expedited through China's two-year-old special approval procedure, or "green channel.